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Background: Metabolic syndrome (MS) has been shown to increase the risk of breast cancer. Existing data suggest
that the strength of metabolic syndrome-breast cancer link varies by intrinsic molecular subtype, but results from
worldwide literature are controversial. Primary endpoint of the study was to assess whether MS is a predictor of
specific breast cancer (BC) subtype. Secondary endpoint was to determine whether components of MS can indi-
vidually increase the risk of specific breast cancer subtype.
Methods: Anthropometric and metabolic variables were correlated to breast cancer specific subgroups,
retrospectively. Statistical significance was considered when p ≤ 0.05 and 95% CI.
Results: Data analysis suggests that MS per se represents a modifiable risk factor for BC in postmenopausal [OR 6.28
(95% CI 2.79-14.11) p < 0.00001]. MS per se prevalence is higher among Luminal breast cancers in postmenopausal
[OR 1.37 (95% CI 1.07-2.80) p = 0.03]. Body Mass Index (BMI) alone is associated to Luminal A subtype breast cancer risk
[OR 1.12 (95% CI 0.96-2.196 p = 0.2]. Waist Circumference > 88 cm has been shown to be specifically and statistically
significant associated to HER-2+ breast cancer subtypes in postmenopausal [OR 2.72 (95% CI 1.69- 10.72) p = 0.01],
whilst in Luminal B it was only marginally statistical associated [OR 2.21 (95% CI 0.77-2.60) p = 0.1]. Insulin resistance
showed statistical significant association to HER-2+ and Luminal B tumors [OR 2.11 (95% CI 1.66-6.69) p = 0.05] and
[OR 2.33 (95% CI 1.2-4.2) p = 0.006], respectively. Hence, it has emerged that BMI is weakly associated to Luminal A
breast cancers in this case series, whereas visceral obesity and insulin resistance are likely to be linked to more
aggressive breast cancer subtypes.
Conclusions: New molecular biomarkers unveiling metabolic syndrome related breast carcinogenesis need to be
detected to further stratify breast cancer risk by subtypes.
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Metabolic syndrome (MS) has been related to the risk
of breast cancer (BC) worldwide [1,2]. MS is a
spectrum of conditions including abdominal obesity, in-
sulin resistance, atherogenic dyslipidemia (manifests in
routine lipoprotein analysis by raised triglycerides and low
concentrations of HDL-Cholesterol) and hypertension.
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unless otherwise stated.Program Adult Treatment Panel III (NCEP ATP III) [3]
are listed in Table 1.
MS has been shown to increase the risk of postmeno-
pausal breast cancer, whilst no sufficient data on premen-
opausal setting have been published to date [4-7]. As
features of MS, both visceral obesity and insulin resist-
ance are mainly correlated to metabolic syndrome breast
cancers in postmenopausal [6]. Obesity can promote car-
cinogenesis both directly and indirectly [8]. The aromatase
enzyme synthesizes estrogens in adipose tissue from circu-
lating androgens, hence directly stimulating breast cells to
proliferate. As an indirect effect the presence of visceral
obesity impacts on cell sensitivity to insulin activity andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 ATP III clinical identification of metabolic
syndrome [3]
Risk factor Defining level
Abdominal obesity, given as waist circumference* Women > 88 cm
Triglycerides ≥150 mg/dL
HDL – cholesterol <50 mg/dL
Blood pressure ≥130/≥85 mm Hg
Fasting glucose ≥110 mg/dL
*Overweight and obesity are associated with insulin resistance and the
metabolic syndrome. However, the presence of abdominal obesity is more
highly correlated with the metabolic risk factors than is an elevated BMI.
Therefore, the simple measure of waist circumference is recommended to
identify the body weight component of the metabolic syndrome.
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consequence, a balancing mechanism raises insulin
releasing, thus resulting in a chronic compensatory
hyperinsulinemic state. High levels of circulating insu-
lin turn into aberrantly mitogenic and antiapoptotic
effects [9,10]. High concentrations lead insulin to act
as a growth factor peptide by binding the insulin-like
growth factor-1 receptor (IGF-1R) [11,12].
Growing evidence indicates a key role of the IGF-1/
IGF-R system in regulating insulin sensitivity. There is
substantial experimental evidence that the growth hor-
mone/insulin IGF-1 axis not only affects the proliferative
behaviour of breast cancer, but also stimulates prolifer-
ation of normal breast epithelial cells [13]. As a matter
of the fact, low IGF-1 bioactivity in centenarians’off-
spring has been shown to be inversily associated to
cancer (p = 0.06) [14].
In vitro and in vivo studies have shown insulin receptor
overexpression in breast tissue. Furthermore, it seems that
high insulin levels can alter the levels of IGF-binding pro-
teins, which regulate the amount of bioactive insulin or
IGFs in the microenvironment, thereby resulting in im-
paired insulin signalling [8]. The IGF-1 signaling pathway
activates several downstream signals important to breast
cancer development and survival [15] and has been also
implicated in resistance to cytotoxic therapies [11].
Breast cancers are multiple distinct diseases, with intrin-
sic molecular subtypes categorized as Luminal A, Luminal
B, human epidermal growth factor receptor 2 positive
(HER-2+) and Triple Negative (TN) [16]. Existing data
suggest that the strength of the metabolic syndrome-
breast cancer link varies by intrinsic cancer subtype.
BMI has been shown to be more likely associated with
hormone receptor-positive tumors [17-19]. Moreover
recent studies confirm that obesity negatively impacts
on overall survival and cumulative incidence of distant
metastasis in specific molecular subtypes (e.g. HER-2+)
[20]. In the last decade molecular profiles and gene
assay have been contributing to highlight the heteroge-
neous nature of breast cancer. Hence, main aim of thisstudy was to assess whether MS is a predictor of spe-
cific breast cancer subtype. Secondary endpoint was to
determine whether components of MS can individually
increase the risk of specific breast cancer subtype.
Methods
This study consisted of 500 women diagnosed with breast
cancer and treated within the Department of Breast
Surgery at National Cancer Institute of Naples in 2013.
Cases with missing data regarding metabolic parameters
(n = 98), estrogen receptor (ER) status (n = 3), progester-
one receptor (PR) status (n = 4) and HER-2 expression
(n = 12) have been excluded. After missing data exclu-
sion, 383 cases of invasive breast cancer were regarded
as eligible for retrospective analysis.
Measures and assay methods
Anthropometric and metabolic parameters were recorded
accurately at the time of admission after patients had been
consented for data collection, sharing and archiving. Body
Mass Index (BMI) (kg/m2) was calculated from weight
and height values and stratified by the World Health
Organization criteria (<25 kg/m2 = underweight/nor-
mal, ≥25 kg/m2 = overweight/obese). Waist circumfer-
ence (WC) > 88 cm was regarded as the cut-off value of
visceral obesity. The waist and hip ratio (WHR) was
obtained from waist and hip circumference, measuring
the smallest circumference of both to discriminate be-
tween android and gynoid fat distribution. Cut-off for
android fat distribution obesity was WHR > 0.8. Fasting
plasma glucose, insulin, HDL-Cholesterol (HDL-C)
and triglycerides serum levels were assessed from blood
samples database. Fasting plasma glucose, HDL-C and tri-
glycerides were measured according to the NCEP ATP III
criteria. Blood samples were locally assessed at the central
laboratory of the National Cancer Institute at the time of
diagnosis. Fasting plasma glucose measurement was deter-
mined by the COBAS INTEGRA Glucose HK cassette
(GLUC2). It contains an in vitro diagnostic reagent system
intended for use on COBAS INTEGRA systems for the
quantitative determination of the glucose concentration
in hemolysate. Electrochemiluminescence immunoassay
(ECLIA) applied on Cobas 6000 was used for insulin
concentration measurement. Enzymatic colorimetric test
CHOD – POD was employed for cholesterol dosage. The
GPO - POD method based on the enzymatic determin-
ation of glycerol using the enzyme glycerol phosphate oxi-
dase (GPO) has been used for triglycerides quantification.
Fresh, clear, unhemolyzed serum has been the specimen
of choice. Specimen-collection followed the NCCLS docu-
ment H4-A3 guidelines. Cut-off for hyperinsulinemia was
fasting plasma insulin level > 25 mcU/ ml. Insulin resist-
ance was calculated by the homeostasis model assessment
ratio-insulin resistance (HOMA1-IR) [10,21]. The original
Table 2 Metabolic syndrome prevalence by different
breast cancer subtypes among postmenopausal women
MS prevalence OR p
LUMINAL (Luminal
A + Luminal B)
62.7% 1.37(1.07-2.80) 0.03
LUMINAL A 25.5% 0.71 (0.41-1.21) 0.2
LUMINAL B 37.5% 1.74 (0.99-3.06) 0.06
HER-2+ 20% 0.60 (0.19-1.86) 0.38
TN 25.8% 0.85 (0.36-1.0) 0.71
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has been widely used in epidemiological and clinical
studies. Recently the model was updated to a computer
version (HOMA2-IR) [22]. The HOMA2-IR index can
be obtained by the program HOMA Calculator v2.2.2.
Several studies have established population-specific
cut-off points to identify insulin-resistance and meta-
bolic syndrome using the original HOMA1-IR index;
however, cut-off values for HOMA2-IR are scarce [23,24].
Hence, HOMA1-IR was used to calculate insulin-resistance
as in previous studies.
Diagnosis of MS was by NCEP-ATP III criteria [3]. All
patients (pts) presenting with at least three of five cri-
teria listed by the NCEP-ATP III report [3] have been
diagnosed with MS. Menopausal status; endocrine re-
ceptors; HER-2 expression and Ki67 proliferation index
were searched in the medical record review. The study
was approved by the National Cancer Institute Ethical
Committee, from Register M1/2 - metabolic syndrome,
insulinemia, BMI in breast cancer prevention.
Immunohistochemical analysis
ER and PR status were assessed by immunohistochemistry
(IHC). Staining for estrogen receptors (ER) and progester-
one receptors (PR) was scored according to the method
described by Allred DC et al [25] and human epidermal
growth factor receptor 2 (HER-2) staining according to
the criteria used for the Herceptest [26]. HER-2 positivity
(a score of 3+) was defined as a strong complete mem-
brane staining in more than 10% of tumor cells; scores of
0 and 1 were considered negative and fluorescence in situ
hybridization (FISH) was done for all 2+ tumors. Ki67
proliferation index was assessed by using Mib-1 mono-
clonal antibody (1:200 Dako) [27]. Ki67 was categorized
as low (≤20%) or high (>20%) [27]. The evaluation of
immunostaining was blinded to the outcome. The mo-
lecular categories have been correlated with immunohisto-
chemical biomarkers. Tumor subtypes were classified as
Luminal A (ER positive and/or PR positive/HER-2
negative, Ki67 ≤ 20%); Luminal B ( ER positive and/or
PR positive/HER-2 positive, Ki67 > 20%); HER-2 posi-
tive (ER negative/PR negative/ HER-2 positive/any
Ki67) and TN ( ER negative/PR negative/ HER-2 negative/
any Ki67, cytokeratin 5/6 positive and/or epidermal growth
factor receptor positive) according to the latest St. Gallen
International Expert Consensus Recommendations [28].
Statistics
Differences in the distribution of both tumor characteris-
tics and metabolic features between groups were analyzed
by the Pearson Chi-square test and Student’s test. Analysis
was done to assess the association of breast cancer
subtype with the aforesaid variables (menopausal status,
triglycerides, HDL-C, BMI, WC, WHR, hypertension,serum glucose, insulin and HOMA-IR). Tumors were
grouped into Luminal A, Luminal B, HER-2+ and TN
breast cancers. Odds ratio (OR) and confidence intervals
(95% CI) were measured by using multivariate logistic
regression analysis to determine whether metabolic risk
factors could impact on specific breast cancer subtype.
One sample Kolmogorov-Smirnov test was performed to
check the normal distribution of variables. Variables were
normally distributed (p > 0.05). By using logistic regression
analysis Luminal A and Luminal B cancers were analyzed,
independently. Multivariate analyses were adjusted for the
type of menopause. Data were collected and analyzed by
using Statistical Package for Social Sciences version 20
(IBM SPSS). Statistical significance was considered when
p ≤0.05 and 95% CI.
Results and discussion
The analysis included a total of 383 female cases pre-
senting with BC. 266 (70%) were postmenopausal and
117 (30%) were premenopausal at the time of diagnosis.
Mean age was 56.68 ± 13.11 years. The whole cohort of
383 pts comprised 46 triple negative cancers; 27 HER-2+
cancers and 310 Luminal cancers (191 Luminal A and 119
Luminal B), in accordance with the approximate preva-
lence of breast cancer subtypes emerged from landmark
studies [29].
Primary endpoint of the study was to assess whether
MS is a predictor of specific breast cancer subtype.
Secondary endpoint was to determine whether singular
features of MS can increase the risk of specific breast
cancer subtype.
MS prevalence has been found to be higher in postmen-
opausal setting than in premenopausal [28.57% vs 5.98%
p = 0.05]. MS in postmenopausal has been found to in-
crease BC risk [OR 6.28 (95% CI 2.79-14.11) p < 0.00001].
As primary endpoint it has emerged that MS preva-
lence was 62.7% among patients diagnosed with Luminal
cancers [OR 1.37 (95% CI 1.07-2.80) p = 0.03]. By splitting
Luminal tumors in Luminal A and Luminal B, it has
emerged that MS prevalence was 25.5% among Luminal A
tumors [OR 0.71 (95% CI 0.41-1.21) p = 0.2], whilst 37.5%
among Luminal B subtypes [OR 1.74 (0.99-3.06 p = 0.06)],
a trend towards significance. Table 2 shows MS prevalence
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women.
MS prevalence in premenopausal was found to be 8.7%
among Luminal cancers; 13% among TN; 14% among
HER-2+ without showing statistical significance.
Mean BMI was 27.20 ± 5.45. BMI ≥ 25 kg/m2 was
found in 57.4% of the whole cohort. BMI showed sig-
nificantly different distribution (p = 0.004) among the
four specific breast cancer subtypes. Luminal A sub-
type was found to be associated to overweight and
obesity expressed in BMI [OR 1.12 (95% CI 0.96-2.39
p = 0.2], a very slight trend toward significance, as
shown in Table 3.
Mean WC was 91.41 ± 15.0 cm. The whole cohort pre-
sented with a visceral obesity (WC > 88 cm) prevalence of
52%. WC> 88 cm showed different distribution among
groups. WC> 88 cm was measured in 55.55% of HER-2+
BC; 52.25% of Luminal BC and 47% of TN (p = 0.0065).
WC > 88 cm was associated to increased risk of breast
cancer in HER-2+ subtypes and a little significant in
Luminal B subtypes. 56.3% of HER2+ BC presented
with WC> 88 cm [OR 2.72 (95% CI 1.69- 10.72) p = 0.01].
55.6% of Luminal B cancers presented with WC> 88 cm
[OR 2.21 (95% CI 0.77-2.60) p = 0.1], whilst 49.7% of
Luminal A cancers presented with WC> 88 cm [OR 1.12
(0.65-1.91) p 0.6]. TNBC presented with WC > 88 cm in
47.8% [OR = 0.91 (0.66-1.25) p = 0.1].
Mean WHR was 0.86 ± 0.090 cm. The whole cohort
presented with WHR > 0.8 was in 76% of the cases.
WHR > 0.8 was found in 81.48% of HER-2+ BC; 76.12% of
Luminal BC and 69.56% of TN (p = 0.0037). Waist/hip
ratio (WHR) > 0.8 cm was associated to increased risk of
BC in HER-2+ cancers, but did not reach the predefined
level of significance [OR 1.89 (95% CI 1.6-4.1) p = 0.8].
Mean HOMA-IR was 3.02 ± 2.09. The whole cohort
presented with HOMA-IR ≥ 2.5 in 48.5% of cases. Half
of them [52.63% (p = 0.0024)] were HER-2+ tumors.Table 3 Odds ratios and 95% confidence intervals for BMI an
subtypes
Risk factor Luminal A breast
cancer (n = 191)
Luminal B breast
cancer (n = 119 )
OR (CI 95%) p OR (CI 95%)
BMI ≥ 25 Kg/m2 1.12 (0.96-2.39) 0.2 0.97 (0.46-1.99)
WC ≥ 88 cm 1.12 (0.65-1.91) 0.6 2.21 ( 0.77-2.60)
WHR ≥ 0.8 0.9 (0.45-1.73) 0.7 0.92 (0.45-1.87)
HOMA-IR 0.68 (0.39-1-19) 0.1 2.33 (1.2-4.2)
Serum fasting glucose 1.21 (0.70-2.08) 0.1 1.5 (0.9-2.1)
Hyperinsulinemia 0.99 (0.44-2.19) 0.9 0.51 (0.21-1.24)
Hypertension 0.51 (0.30-0.88) 0.1 1.35 (0.76-2.41)
Triglycerides 0.64 (0.32-1.29) 0.2 1.31 (0.62-2.78)
HDL-Cholesterol 1.12 (0.65-1.91) 0.6 1.15 (0.65-2.05)HOMA-IR ≥ 2.5 was found to be positively associated
to HER-2+ (OR 2.11 (95% CI 1.66-6.59) p value 0.05 and
Luminal B cancers [OR 2.33 (95% CI 1.2-4.2) p 0.006].
Whole cohort fasting plasma glucose ≥ 110 mg/dl preva-
lence was 15% (mean glucose serum levels 99.45 ± 26.5).
Distribution among groups was 14.8% in HER-2+ BC [OR
1.34 (CI 95% 0.34-5.3 p = 0.6]; 16% in Luminal cases [OR
1.5 (95% CI 0.9-2.1) p = 0.06 for Luminal B] and [OR 1.21
(95% CI 0.70-2.08) p = 0.1 for Luminal A] and 8% in
TNBC [OR 0.59 (95% CI 0.17-1.9) p = 0.3].
95% of HER2 + BC presented with hyperinsulinemia,
whereas Luminal B were 90%; Luminal A were 88%; TN
were 74%, but no statistical relevant association was found.
Hypertension prevalence was 39.2% in the whole
cohort. Hypertension was found in 22.22% of HER-2+
BC, 41.29% of Luminal tumors; 34% of TNBC. It showed
association with breast HER-2 + BC [OR 3.27 (95% CI
0.95-11.26) p = 0.06], falling just over the limits of statis-
tical significance.
Mean HDL-Cholesterol levels were 58.64 ± 15.11.
Whole cohort HDL-Cholesterol ≤ 50 mg/dl prevalence
was 27.9%. No statistically significant results were found
among subgroups.
Mean triglycerides blood levels were 100.14 ± 56.28 mg/dl.
Hypertriglyceridemia prevalence was found to be 11.11%
in the whole cohort. No specific association with breast
cancer subtypes and no statistically significant differences
were found.
Data analysis suggests that MS increases the risk of
BC [OR 6.28 (95% CI 2.79-14.11) p < 0.00001]. MS
prevalence is higher among Luminal tumors in post-
menopausal. Moreover, MS seems to be carry a major
weight in increasing Luminal B breast cancer risk [OR
1.74 (0.99-3.06 p = 0.06)] rather than Luminal A in this
cohort, even if just on the verge of significance.
BMI alone is associated to Luminal A subtype breast
cancer risk [OR 1.12 (95% CI 0.96-2.39 p = 0.2], a veryd metabolic syndrome single features by breast cancer
HER-2+ breast
cancer (n = 27)
Triple Negative breast
cancer (n = 46)
p OR (CI 95%) p OR (CI 95%) p
0.9 0.54 (0.23-1.28) 0.1 0.50 (0.16-1.45) 0.2
0.1 2.72 (1.69-10.72) 0.01 0.91 (0.66-1.25) 0.1
0.8 1.89 (1.6-4.1) 0.8 0.61 (0.21-1.74) 0.4
0.006 2.11 (1.66-6.59) 0.05 1 (0.7-1.4) 0.1
0.6 1.34 (0.34-5.3) 0.6 0.59 ( 0.17-1.9) 0.3
0.1 0.44 (0.05-3.92) 0.4 0.21 (0.0700.65) 0.7
0.3 3.27 (0.95-11.26) 0.06 0.69 (0.28-1.70) 0.4
0.4 1.48 (0.29-7.41) 0.6 0.74 (0.22-2.44) 0.6
0.6 1.08 (0.59-1.95) 0.5 1.5 (0.67-3.46) 0.3
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ment with existing data on a large population [18], sug-
gesting that reducing BMI can be helpful in preventing
and treating Luminal A breast cancers. Association of
BMI and Luminal A breast cancers can be explained by
the direct effect of aromatase enzyme within the adipose
tissue.
WC > 88 cm and insulin resistance have been shown
to be specifically and statistically significant associated
to HER-2+ and, marginally to Luminal B breast cancers
in postmenopausal. Hence, it has emerged that visceral
obesity (android fat distribution) and insulin resistance
are likely to be associated to more aggressive breast
cancer subtypes. As a matter of the fact Luminal B
breast subtypes can include both of those cancers
presenting with receptors positive and overexpressing
the HER-2 oncogene. Therefore it might result in more
aggressive BC promoted by the indirect and synergistic
pro-inflammatory and mitogenic effects of both visceral
obesity and insulin resistance.
Consistent with this evidence, discussion is opened to
new questions about different proliferation pathways
involving metabolism related breast cancers. In previous
published studies we found WC and insulin resistance to
be pivotal in breast cancer risk assessment. Both pro-
inflammatory and mitogenic effects have been highlighted,
independently of BMI [6,10]. Now, a step forward to more
specific risk assessment might be taken.
HDL-C and triglycerides are no specifically associated
to breast cancer risk within the analyzed cohort.
Despite results are encouraging and stimulating the
current study has been conducted on a modest sample
size and further analyses on larger samples are needed.
Conclusions
MS per se has been shown to represent a modifiable
risk factor for BC in postmenopausal [OR 6.28 (95%
CI 2.79-14.11) p < 0.00001]. Luminal tumors are more
likely to be influenced by MS. BMI alone has been
shown to impact on Luminal A subtypes, even though
with a slight slide towards significance whilst WC
and insulin resistance are indicator of more aggres-
sive breast cancer risk (e.g. HER2+ and Luminal B
tumors). Considering the great heterogeneity in breast
cancer specific subtypes, further studies on larger
samples are needed to investigate the link to metabolic
syndrome features and to focus on modifiable risk fac-
tors intervention. New molecular biomarkers unveil-
ing MS related breast carcinogenesis need to be
detected to further stratify individual breast cancer
risk by subtype. Different molecular pathways involved
in breast carcinogenesis are expected to be found and
targeted at different steps in breast cancer prevention
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